This Article Abstract Full Text (PDF) All Versions of this Article: 106/21/2659    most recent 01.CIR.0000038364.26310.BDv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brunner, E.J. Articles by Marmot, M.G. Search for Related Content PubMed PubMed Citation Articles by Brunner, E.J. Articles by Marmot, M.G. Related Collections Epidemiology Autonomic, reflex, and neurohumoral control of circulation Glucose intolerance Related Article

(Circulation. 2002;106:2659.)
© 2002 American Heart Association, Inc.

Clinical Investigation and Reports

Adrenocortical, Autonomic, and Inflammatory Causes of the Metabolic Syndrome

Nested Case-Control Study

E.J. Brunner, PhD; H. Hemingway, MRCP; B.R. Walker, MD; M. Page, MRes; P. Clarke, PhD; M. Juneja, BSc; M.J. Shipley, MSc; M. Kumari, PhD; R. Andrew, PhD; J.R. Seckl, MBBS, PhD; A. Papadopoulos, PhD; S. Checkley, FRCP; A. Rumley, PhD; G.D.O. Lowe, MD, FRCP; S.A. Stansfeld, PhD; M.G. Marmot, PhD, FRCP

From the International Centre for Health and Society, Department of Epidemiology and Public Health, University College London, England; Endocrinology Unit (B.R.W., R.A., J.R.S.), Western General Hospital, University of Edinburgh, Scotland; Institute of Psychiatry (A.P., S.C.), Bethlem Royal Hospital, London, England; Department of Medicine (A.R., G.D.O.L.), Royal Infirmary, University of Glasgow, Scotland; and Department of Community Psychiatry (S.A.S.), Queen Mary and Westfield College, London, England.

Correspondence to E.J. Brunner, PhD, International Centre for Health and Society, Department of Epidemiology and Public Health, University College London, 1-19 Torrington Place, London, England. E-mail e.brunner{at}ucl.ac.uk

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background— The causes of metabolic syndrome (MS), which may be a precursor of coronary disease, are uncertain. We hypothesize that disturbances in neuroendocrine and cardiac autonomic activity (CAA) contribute to development of MS. We examine reversibility and the power of psychosocial and behavioral factors to explain the neuroendocrine adaptations that accompany MS.

Methods and Results— This was a double-blind case-control study of working men aged 45 to 63 years drawn from the Whitehall II cohort. MS cases (n=30) were compared with healthy controls (n=153). Cortisol secretion, sensitivity, and 24-hour cortisol metabolite and catecholamine output were measured over 2 days. CAA was obtained from power spectral analysis of heart rate variability (HRV) recordings. Twenty-four-hour cortisol metabolite and normetanephrine (3-methoxynorepinephrine) outputs were higher among cases than controls (+ 0.49, +0.45 SD, respectively). HRV and total power were lower among cases (both -0.72 SD). Serum interleukin-6, plasma C-reactive protein, and viscosity were higher among cases (+0.89, +0.51, and +0.72 SD). Lower HRV was associated with higher normetanephrine output (r=-0.19; P=0.03). Among former cases (MS 5 years previously, n=23), cortisol output, heart rate, and interleukin-6 were at the level of controls. Psychosocial factors accounted for 37% of the link between MS and normetanephrine output, and 7% to 19% for CAA. Health-related behaviors accounted for 5% to 18% of neuroendocrine differences.

Conclusions— Neuroendocrine stress axes are activated in MS. There is relative cardiac sympathetic predominance. The neuroendocrine changes may be reversible. This case-control study provides the first evidence that chronic stress may be a cause of MS. Confirmatory prospective studies are required.

Key Words: norepinephrine • coronary disease • stress • metabolism • heart rate

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
There is a widespread and strong inverse association between socioeconomic position and risk of coronary heart disease (CHD).¹ The Whitehall II study is investigating reasons for this phenomenon^2,3 and has shown that there is a close relationship between lower social position and increased probability of having the metabolic syndrome and raised levels of associated inflammatory variables.^3,4 There may be a psychosocial explanation for these findings.^5–7 Consistent with such mechanisms, there have been reports of links between components of the metabolic syndrome and aspects of autonomic and neuroendocrine function.^8–13 We therefore set out to test systematically the hypothesis that altered autonomic and neuroendocrine function is a feature of the metabolic syndrome in a population-based sample.

See p 2634

We conducted a nested case-control study of the metabolic syndrome. Its aims are to examine (1) the strength of associations of prevalent metabolic syndrome caseness with measures of hypothalamic-pituitary-adrenocortical (HPA), sympatho-adrenal medullary and cardiac autonomic activity, inflammatory and hemostatic markers, and adrenal androgen output; (2) reversibility of the biologic changes associated with the syndrome; and (3) psychosocial and behavioral explanations for the neuroendocrine and other disturbances associated with metabolic syndrome caseness.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
We conducted a case-control study nested within the Whitehall II cohort,² with double-blind assessment of neuroendocrine variables, restricted to men for reasons of economy. CHD risk factor and cardiac measures were collected at phase 5 (third clinic examination, 1997 to 1998). Neuroendocrine measurements were collected at later workplace visits. The University College London research ethics committee approved the study protocol, and participants gave informed consent.

Case Definition
Cases of metabolic syndrome were participants with 3 or more of the following 5 risk factors in the adverse quintile at phase 5: 2-hour glucose (>7.25 mmol/L [131 mg/dL]), systolic blood pressure (>136 mm Hg), fasting triglycerides (>1.90 mmol/L [168 mg/dL]), HDL cholesterol (<1.10 mmol/L [43.6 mg/dL]), and waist to hip ratio (>0.977). Diabetics and those on hypotensive medication were assigned to the top glucose and blood pressure quintiles, respectively. For comparison, a case-control analysis using the later-defined ATPIII definition¹⁴ of metabolic syndrome is shown (Table 1).

View this table: [in this window] [in a new window]   TABLE 1. HPA Axis and Autonomic Function, Adrenal Androgen Output, Inflammatory and Hemostatic Factors in Metabolic Syndrome Cases and Controls: Quintile and ATPIII Definitions of Metabolic Syndrome

Study Sample
Because of the low prevalence of the metabolic syndrome (12%), the study was designed to have 3 controls per case. For 90% power to detect a mean case-control difference of 0.5 SD in outcome variables at a significance level of 0.05, the sample size required was 224. Men working in London civil service offices at phase 5 were selected from the cohort according to presence or absence of metabolic syndrome at phase 3 (second clinic examination, 1991 to 1993).³ A research nurse, blinded to case-control status, recruited participants at the phase 5 clinic. Participants were excluded if they had used inhaled or oral steroids within the past 3 months. Of the 283 men invited to participate, 63 refused, giving a response rate of 77.7% (n=220). To avoid dilution of case-control differences, participants who were metabolic syndrome cases at phase 3 but not at phase 5 (n=23) were defined as ex-cases and excluded from the control group. Caseness at phase 5 could not be defined for 14 participants because of incomplete data, yielding 30 cases and 153 controls. Of the 30 cases, 23 had had the metabolic syndrome at phase 3. This final sample gave a power of 62% to detect a 0.5 SD difference between cases and controls.

Urinary Catecholamines, Cortisol, and Androgens
A research nurse visited each participant 3 times at his workplace on consecutive days. At visit one, the participant was given a calibrated urine bottle (2500 mL) containing preservative (10 mL 150 g/L ascorbic acid) for timed 24-hour urine collection. At visit 2 (the next day), the nurse collected a 20 mL sample that was frozen (-80°C) on the same day. Urine was analyzed for cortisol and adrenal androgen metabolites using GC-MS and metanephrine and normetanephrine using radioimmunoassay.

Salivary Cortisol and Skin Vasoconstrictor Sensitivity to Glucocorticoids
Participants collected saliva at 4.30 PM and 10 PM on 2 consecutive working days in a Salivette (Sarstedt). Participants recorded potential acute influences on cortisol level, such as difficult tasks or conversations or consumption of cigarettes or food in the hour before sampling. Salivary cortisol was measured by fluoroimmunoassay using rabbit anti-cortisol antiserum.¹⁵ The intra-assay coefficient of variation was 8.8% at 0.3 nmol/L and 6.6% at 4.7 nmol/L. The skin vasoconstriction assay was carried out as a measure of glucocorticoid sensitivity.¹⁶

Biomedical Examination
Clinic examination included resting blood pressure, ECG, weight, height, and waist and hip circumference. Venous blood was taken in the fasting state or at least 5 hours after a light, fat-free breakfast before undergoing a 2-hour 75-g oral glucose tolerance test. Blood was anticoagulated with EDTA (viscosity) or citrate (hemostatic markers). Plain serum and plasma were stored at -80°C until analysis. Plasma viscosity was measured at 37°C in a Coulter capillary viscometer. Plasma fibrinogen (Clauss method), von Willebrand factor, fibrin D-dimer, and tissue plasminogen activator (t-PA) antigen were measured as previously described.¹⁷ Serum interleukin-6 (IL-6) was assayed using a high-sensitivity two-site ELISA kit. Plasma C-reactive protein (CRP) was determined using automated turbidimetry. Serum amyloid A (SAA) was measured by latex nephelometry. Serum cholesterol and triglycerides were measured by automated enzymic colorimetric methods. HDL cholesterol was measured using phosphotungstate precipitation. Glucose was measured in fluoride plasma by an electrochemical glucose oxidase method.

Heart Rate Variability
After 5 minutes of rest in a quiet room, a digitized recording (5 minutes) was made of supine beat-to-beat heart rate (R waves).¹⁸ Computerized QRS detection and ectopic beat identification were used. In comparison with cardiologist review, the algorithm had high sensitivity (92%) and specificity (95%) for the detection of supraventricular ectopic beats with normal QRS complexes. Time domain measures derived from these data were heart rate and heart rate variability (SD of RR intervals). Frequency domain measures (Blackman-Tukey method) included total power (0.04 to 0.4 Hz) and low-frequency (LF, 0.04 to 0.15Hz) and high-frequency (HF, 0.15 to 0.4Hz) power. HRV data are missing for 37 (17%) subjects.

Questionnaire
The phase 5 health questionnaire included questions on civil service employment grade, work characteristics (decision latitude, job demands, social support at work), estimated value of household assets (house, contents, car, savings less debt), dietary pattern (usual kind of bread and milk, frequency of eating fresh fruit and vegetables), physical activity (moderate activity quartile and vigorous activity category based on recall of past 4 weeks’ activities), smoking habit (current, past, or never smoker), and alcohol consumption (quintiles based on units consumed in previous week). The 3 job strain scale scores were obtained by summing item scores from the Karasek-Theorell questionnaire.

Statistical Methods
Table 1 presents the case-control analysis (see Case Definition above). ANOVA was used to test for case-control differences. Outcome variables with skewness 1 were log transformed. Means were adjusted for age by stratifying into 5-year age groups. Table 2 tests the reversibility of the case-control differences in outcome variables by comparing these differences, where statistically significant, for cases as in Table 1 and the group of ex-cases (see Study Sample above). Outcome variables have been standardized to have mean score of 0 and SD of 1, so that differences can be compared on the same scale. Tables 3 and 4 examine statistical explanations for the observed case-control differences using multiple linear regression. Prespecified variables or factors were added to the age-adjusted model, first singly and then in combination. The resulting percentage change (generally a reduction) in the case-control difference estimates how much the explanatory factors account for the observed difference. Participants with incomplete data were excluded from analyses. Table 3 analyzes the ability of psychosocial factors to explain the autonomic and other differences related to the metabolic syndrome, whereas Table 4 does the same with behavioral factors.

View this table: [in this window] [in a new window]   TABLE 2. Phase 5 Metabolic Syndrome Cases and Ex-Cases: Standardized Differences From Controls in Neuroendocrine, Hemostatic, and Inflammatory Measures

View this table: [in this window] [in a new window]   TABLE 3. Change Due to Adjustment for Psychosocial and Material Factors in Case-Control Differences in Neuroendocrine, Autonomic, Inflammatory, and Hemostatic Measures

View this table: [in this window] [in a new window]   TABLE 4. Change Due to Adjustment for Health-Related Behaviors in Case-Control Differences in Neuroendocrine, Autonomic, Hemostatic, and Inflammatory Measures

Multiple imputation (Norm software)¹⁹ of variables used to define caseness was used to assess potential selection bias attributable to the exclusion from analysis of 14 participants with incomplete data. There were trivial differences (<2%) between multiple-imputation results and those based on excluding the subjects with unknown caseness.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Demographic characteristics of the 63 nonparticipants were compared with the 220 men who accepted (mean age, 51.8 years). Refusers were 1.6 years older and in lower employment grades (both P<0.05). The percentages married (participants 78%, refusers 83%) and with metabolic syndrome at phase 5 (participants 15%, refusers 17%) were similar.

The quintile and ATPIII definitions of metabolic syndrome produced an identical pattern of case-control differences (Table 1). Means for the two overlapping groups of controls were similar, and only data for the control group based on the quintile definition are shown. Urinary cortisol metabolite and normetanephrine outputs were higher in metabolic syndrome cases than in controls. Other measures of HPA function were similar. Resting heart rate was higher, and all HRV measures except LF/HF ratio were lower in cases than controls. Total urinary adrenal androgen output did not differ by caseness, but epiandrosterone tended to be lower among cases. Plasma tPA antigen, viscosity, IL-6, and CRP were higher in cases than controls, but D-dimer, fibrinogen, von Willebrand factor, and SAA were similar in the 2 groups. Cases were more obese than controls (mean body mass index [BMI] difference, 5.3 kg/m² on quintile definition, 6.0 kg/m² on ATPIII definition).

Employment grade was correlated (lower value indicating lower grade) with HRV and total power of HRV (both r=0.20, P=0.02). Serum IL-6 was inversely correlated with HRV (r=-0.20, P<0.02).

Table 2 compares differences from controls in mean levels of outcome variables in 2 groups: phase 5 cases, as Table 1, and ex-cases, who had metabolic syndrome at phase 3 but not at phase 5. There was no evidence of regression to the mean among outcome variables in these two groups using a graphical method, and therefore variables not differing significantly by caseness were dropped from Table 2. Between phases 3 and 5, mean BMI increased 1.0 kg/m² in controls, 1.9 kg/m² in cases, and 0.5 kg/m² in ex-cases (difference from controls, P<0.01, 0.27, respectively). Standardized case-control differences (see Statistical Methods) allow meaningful comparisons across outcomes. Mean levels of all variables except urinary normetanephrine tended to be more favorable in ex-cases than cases. Total cortisol metabolites were 0.5 SD higher in cases than controls but less than 0.1 SD higher in ex-cases. The contrast for IL-6 approached significance.

Psychosocial and material factors partially attenuated the association of metabolic syndrome with catecholamine output and cardiac autonomic function (Table 3). Job strain had a modest explanatory effect for corticosteroid output. Except for t-PA antigen, psychosocial and material factors did not account for the case-control differences in hemostatic and inflammatory variables.

Among the health-related behaviors, smoking and diet had comparatively consistent explanatory effects for HRV and inflammatory variables but not for corticosteroid or normetanephrine output. Physical activity adjustment attenuated case-control differences in t-PA antigen and IL-6. Other attenuations were small. Alcohol intake was not an important determinant, except for corticosteroid output and heart rate. Adjustment for all health behaviors attenuated neuroendocrine differences modestly (change -7%), whereas heart rate and inflammatory marker differences were attenuated by approximately one fifth. Differences in BMI accounted statistically for one third to two thirds of the case-control differences in outcome variables, except urinary normetanephrine (-23%). BMI is closely associated with waist to hip ratio (r=0.7), one of the five variables used to define metabolic syndrome. Taken together, degree of obesity and health behaviors accounted for 44% to 94% of the case-control differences in the outcome variables, with the exception of urinary normetanephrine (-29%).

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
Metabolic syndrome was associated with raised 24-hour cortisol metabolite and normetanephrine output and even more strongly with cardiac autonomic activity. The study demonstrates that function of both major neuroendocrine axes is altered in an important precursor state of CHD. Differences in cortisol output and cardiac autonomic activity associated with metabolic syndrome were reduced in ex-cases, indicating that the changes are at least partially reversible. Psychosocial factors explained a substantial part of the increased normetanephrine output associated with metabolic syndrome. Adverse cardiac autonomic function related to the syndrome was attributable both to psychosocial factors and degree of obesity. The direction of causality cannot be inferred from case-control studies; however, the findings are consistent with our hypothesis that an adverse psychosocial environment contributes to development of metabolic syndrome.

The results add to prospective data from the full Whitehall II cohort²⁰ and elsewhere²¹ that adverse psychosocial conditions in adulthood are associated with an increased risk of CHD. Thus, metabolic syndrome may be an intermediate on the pathway between long-term psychosocial stress and coronary disease.

Metabolic syndrome cases were more obese than controls, and degree of obesity accounted for approximately half of case-control differences in cortisol, cardiac autonomic, and inflammatory measures. Given that another closely related measure of obesity (waist to hip ratio) is part of the case definition, the effect of BMI adjustment is difficult to interpret. Obesity may lead to neuroendocrine and other alterations, including higher cortisol output¹¹ and serum IL-6 level.²² The observed associations may also reflect neuroendocrine origins of metabolic syndrome. Cushing’s syndrome is one model for such a mechanism.

Heart rate variability characterizes autonomic influences on the heart, including anxiety,^23,24 and low HRV is a risk factor for CHD.²⁵ Here, power spectral analysis reveals relative sympathetic predominance (lower total and LF power) and lower vagal tone (HF power) in metabolic syndrome cases, a relation shown previously in the ARIC study.⁹ We extend this observation with a case definition based on a glucose tolerance test as well as lipid levels and blood pressure.

The evidence that sympathoadrenal and autonomic activity mediate the link between psychosocial exposures and metabolic syndrome was more consistent than that for HPA activity. Compared with HRV and catecholamine metabolite output,²⁶ salivary cortisol secretion exhibits greater biological variability (intraclass correlation of 0.3 over 2 days), and this may account for our null findings. Alternatively, higher corticosteroid excretion in the metabolic syndrome may not be accompanied by increased circulating cortisol concentrations if there is raised peripheral cortisol metabolism.¹¹

Our study found several inflammatory and hemostatic factors to be strongly related to the metabolic syndrome,⁴ among them IL-6²² and C-reactive protein. Markers of inflammation predict weight gain,²⁷ diabetes,²⁸ and CHD.²⁹ Previous studies link a low-grade inflammatory response with psychological stress.³⁰ In Whitehall II, raised plasma fibrinogen predicts CHD and is linked with low job control and low employment status.⁵ Here we show the IL-6 level is related to cardiac autonomic activity in healthy controls, as well as being raised among cases.

Individuals classified as cases on two occasions (phases 3 and 5) have, as predicted, a poorer neuroendocrine profile than the ex-cases (phase 3 only). This longitudinal component of the study provides evidence for reversibility of the neuroendocrine and inflammatory alterations linked with the metabolic syndrome. Both allostatic load and physiological interpretations fit with our results. Neuroendocrine changes may precede the physiological alterations,³¹ or HPA and autonomic activity may follow the improvement in the risk factors defining caseness. It may be that both of these mechanisms operate.

Psychosocial measures explained some 13% of case-control differences in HRV indices and 37% of those in normetanephrine, the 3-methoxy metabolite of norepinephrine. In view of the measurement problems associated with determining psychosocial exposure, these are important explanatory effects. BMI in contrast is a more reliable measure and is closely associated with waist to hip ratio and metabolic syndrome variables, but accounted for only 23% of additional normetanephrine output in cases. Normetanephrine output, reflecting total - and ß-adrenergic activity, may rise due to increase in drive from higher centers and the number of adrenergic neurons in adipose tissue. In comparison with the explanatory power of psychosocial factors, health-related behaviors together explained a similar proportion of the metabolic syndrome effect on cardiac autonomic activity and much less of the effect on catecholamine output.

In conclusion, we provide evidence of alterations in function of both major neuroendocrine stress pathways in the metabolic syndrome. Our observation of a simultaneous and strong relation with cardiac autonomic activity invites investigation in the full Whitehall II cohort. Psychosocial factors seem to be putative causal exposures, although the evidence is weaker for the HPA axis than autonomic function. Inflammatory responses, but not adrenal androgen metabolism, seem to be implicated in this relatively early phase of coronary risk development. Additional tests of this hypothesis require studies involving women as well as men and prospective, population-based evidence for the association between psychosocial stress and the metabolic syndrome.

	Acknowledgments

 
The Whitehall II study is supported by grants from the Medical Research Council; British Heart Foundation; Health and Safety Executive; Department of Health; National Heart, Lung, and Blood Institute (HL36310); National Institutes of Health (HS06516); National Institute on Aging (AG13196); and the John D. and Catherine T. MacArthur Foundation. Drs Brunner, Walker, and Shipley are supported by the British Heart Foundation; Dr Hemingway is supported by a Department of Health National Career Scientist Award; and Dr Marmot is supported by a Medical Research Council Research Professorship. We thank participating civil service departments and their welfare, personnel, and establishment officers; the Occupational Health and Safety Agency; the Council of Civil Service Unions; all participating civil servants; the Whitehall II study team; and the European Science Foundation program Social Variations in Health Expectancy in Europe.

Received July 22, 2002; revision received September 6, 2002; accepted September 6, 2002.

	References

Top Abstract Introduction Methods Results Discussion References

 

1. Marmot MG. Inequalities in health. N Engl J Med. 2001; 345: 134–136.[Free Full Text]
   
2. Marmot MG, Davey Smith G, Stansfeld SA, et al. Health inequalities among British civil servants: the Whitehall II study. Lancet. 1991; 337: 1387–1393.[CrossRef][Medline] [Order article via Infotrieve]
   
3. Brunner EJ, Marmot MG, Nanchahal K, et al. Social inequality in coronary risk: central obesity and the metabolic syndrome: evidence from the WII study. Diabetologia. 1997; 40: 1341–1349.[CrossRef][Medline] [Order article via Infotrieve]
   
4. Sakkinen PA, Wahl P, Cushman M, et al. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol. 2000; 152: 897–907.[Abstract/Free Full Text]
   
5. Brunner EJ, Davey Smith G, Marmot MG, et al. Childhood social circumstances and psychosocial and behavioural factors as determinants of plasma fibrinogen. Lancet. 1996; 347: 1008–1013.[CrossRef][Medline] [Order article via Infotrieve]
   
6. Brunner EJ. Stress and the biology of inequality. BMJ. 1997; 314: 1472–1476.[Abstract/Free Full Text]
   
7. Marmot M, Bosma H, Hemingway H, et al. Contribution of job control and other risk factors to social variations in coronary heart disease incidence: Whitehall II Study. Lancet. 1997; 350: 235–239.[CrossRef][Medline] [Order article via Infotrieve]
   
8. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996; 334: 374–381.[Free Full Text]
   
9. Liao D, Sloan RP, Cascio WE, et al. Multiple metabolic syndrome is associated with lower heart rate variability: ARIC study. Diabetes Care. 1998; 21: 2116–2122.[Abstract]
   
10. Phillips DIW, Barker DJP, Fall CHD, et al. Elevated plasma cortisol concentrations: a link between low birth weight and insulin resistance syndrome? J Clin Endocrinol Metab. 1998; 83: 757–760.[Abstract/Free Full Text]
    
11. Andrew R, Phillips DIW, Walker BR. Obesity and gender influence cortisol secretion and metabolism in men. J Clin Endocrinol Metab. 1998; 83: 1806–1809.[Abstract/Free Full Text]
    
12. Berne C, Fagius J, Pollare T, et al. The sympathetic response to euglycaemic hyperinsulinaemia. Diabetologia. 1992; 35: 873–879.[CrossRef][Medline] [Order article via Infotrieve]
    
13. Bjorntorp P, Holm G, Rosmond R. Hypothalamic arousal, insulin resistance and type 2 diabetes mellitus. Diabetes Med. 1999; 16: 373–383.[CrossRef][Medline] [Order article via Infotrieve]
    
14. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486–2497.[Free Full Text]
    
15. Bearn J, Buntwal N, Papadopoulos A, et al. Saliva cortisol during opiate dependence and withdrawal. Addict Biol. 2001; 6: 157–162.[CrossRef][Medline] [Order article via Infotrieve]
    
16. Walker BR, Phillips DI, Noon JP, et al. Increased glucocorticoid activity in men with cardiovascular risk factors. Hypertension. 1998; 31: 891–895.[Abstract/Free Full Text]
    
17. Yarnell JW, Sweetnam PM, Rumley A, et al. Lifestyle and hemostatic risk factors for ischemic heart disease: Caerphilly study. Arterioscler Thromb Vasc Biol. 2000; 20: 271–279.[Abstract/Free Full Text]
    
18. Taskforce of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation. 1996; 93: 1043–1065.[Free Full Text]
    
19. Schafer JL. Analysis of Incomplete Multivariate Data. London: Chapman and Hall; 1997.
    
20. Kuper H, Marmot MG. Decision latitude, job demands, job strain and risk of coronary heart disease within the Whitehall II study. J Epidemiol Commun Health. In press.
    
21. Hemingway H, Marmot M. Psychosocial factors in the aetiology and prognosis of CHD: systematic review of prospective cohort studies. BMJ. 1999; 318: 1460–1467.[Free Full Text]
    
22. Yudkin JS, Kumari M, Humphries SE, et al. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 2000; 148: 209–214.[CrossRef][Medline] [Order article via Infotrieve]
    
23. Kawachi I, Sparrow D, Vokonas PS, et al. Decreased heart rate variability in men with phobic anxiety. Am J Cardiol. 1995; 75: 882–885.[CrossRef][Medline] [Order article via Infotrieve]
    
24. Hemingway H, Malik M, Marmot M. Social and psychosocial influences on sudden cardiac death, ventricular arrhythmia and cardiac autonomic function. Eur Heart J. 2001; 22: 1082–1101.[Free Full Text]
    
25. Liao D, Cai J, Rosamond WD, et al. Cardiac autonomic function and incident coronary heart disease: a population-based case-cohort study: ARIC Study. Am J Epidemiol. 1997; 145: 696–706.[Abstract/Free Full Text]
    
26. Curtin F, Walker JP, Schulz P. Day-to-day intraindividual reliability and interindividual differences in monoamines excretion. J Affect Disord. 1996; 38: 173–178.[CrossRef][Medline] [Order article via Infotrieve]
    
27. Duncan BB, Schmidt MI, Chambless LE, et al. Fibrinogen, other putative markers of inflammation, and weight gain in middle-aged adults: ARIC study. Obes Res. 2000; 8: 279–286.[Medline] [Order article via Infotrieve]
    
28. Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation and prediction of diabetes mellitus in adults: ARIC study. Lancet. 1999; 353: 1649–1652.[CrossRef][Medline] [Order article via Infotrieve]
    
29. Danesh J, Collins R, Appleby P, et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with CHD. JAMA. 1998; 279: 1477–1481.[Abstract/Free Full Text]
    
30. Von Kanel R, Mills PJ, Fainman C, et al. Effects of psychological stress and psychiatric disorders on blood coagulation and fibrinolysis: a biobehavioral pathway to CAD. Psychosom Med. 2001; 63: 531–544.[Abstract/Free Full Text]
    
31. McEwen BS. Protective and damaging effects of stress mediators. N Engl J Med. 1998; 338: 171–179.[Free Full Text]
    

Related Article:

Stress and the Metabolic Syndrome: An Interesting but Enigmatic Association

Paul Hjemdahl
Circulation 2002 106: 2634-2636. [Full Text]

This article has been cited by other articles:

				D. Gozal, O. S. Capdevila, and L. Kheirandish-Gozal Metabolic Alterations and Systemic Inflammation in Obstructive Sleep Apnea among Nonobese and Obese Prepubertal Children Am. J. Respir. Crit. Care Med., May 15, 2008; 177(10): 1142 - 1149. [Abstract] [Full Text] [PDF]

				M. J. Weigensberg, C. M. Toledo-Corral, and M. I. Goran Association between the Metabolic Syndrome and Serum Cortisol in Overweight Latino Youth J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1372 - 1378. [Abstract] [Full Text] [PDF]

				T. Chandola, A. Britton, E. Brunner, H. Hemingway, M. Malik, M. Kumari, E. Badrick, M. Kivimaki, and M. Marmot Work stress and coronary heart disease: what are the mechanisms? Eur. Heart J., March 1, 2008; 29(5): 640 - 648. [Abstract] [Full Text] [PDF]

				V. Vaccarino, C. McClure, B. D. Johnson, D. S. Sheps, V. Bittner, T. Rutledge, L. J. Shaw, G. Sopko, M. B. Olson, D. S. Krantz, et al. Depression, the Metabolic Syndrome and Cardiovascular Risk Psychosom Med, January 1, 2008; 70(1): 40 - 48. [Abstract] [Full Text] [PDF]

				L. G. Futterman and L. Lemberg Inequalities in the Healthcare System: A Problem, Worldwide Am. J. Crit. Care., November 1, 2007; 16(6): 617 - 620. [Full Text] [PDF]

				B. R Walker Glucocorticoids and Cardiovascular Disease Eur. J. Endocrinol., November 1, 2007; 157(5): 545 - 559. [Abstract] [Full Text] [PDF]

				N.G. ABRAHAM, E.J. BRUNNER, J.W. ERIKSSON, and R.P. ROBERTSON Metabolic Syndrome: Psychosocial, Neuroendocrine, and Classical Risk Factors in Type 2 Diabetes Ann. N.Y. Acad. Sci., October 1, 2007; 1113(1): 256 - 275. [Abstract] [Full Text] [PDF]

				J-M Gonzalez-Clemente, C Vilardell, M Broch, A Megia, A Caixas, O Gimenez-Palop, C Richart, I Simon, A Martinez-Riquelme, J Arroyo, et al. Lower heart rate variability is associated with higher plasma concentrations of IL-6 in type 1 diabetes Eur. J. Endocrinol., July 1, 2007; 157(1): 31 - 38. [Abstract] [Full Text] [PDF]

				M.-F. O'Connor, S. J. Motivala, E. M. Valladares, R. Olmstead, and M. R. Irwin Sex differences in monocyte expression of IL-6: role of autonomic mechanisms Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2007; 293(1): R145 - R151. [Abstract] [Full Text] [PDF]

				R. A. Bermudes, P. E. Keck Jr., and J. A. Welge The Prevalence of the Metabolic Syndrome in Psychiatric Inpatients With Primary Psychotic and Mood Disorders Psychosomatics, December 1, 2006; 47(6): 491 - 497. [Abstract] [Full Text] [PDF]

				E. KAJANTIE Fetal Origins of Stress-Related Adult Disease Ann. N.Y. Acad. Sci., November 1, 2006; 1083(1): 11 - 27. [Abstract] [Full Text] [PDF]

				N TENTOLOURIS, S LIATIS, and N KATSILAMBROS Sympathetic System Activity in Obesity and Metabolic Syndrome Ann. N.Y. Acad. Sci., November 1, 2006; 1083(1): 129 - 152. [Abstract] [Full Text] [PDF]

				J. Zhang, R. Niaura, J. R. Dyer, B.-J. Shen, J. F. Todaro, J. M. McCaffery, A. Spiro III, and K. D. Ward Hostility and Urine Norepinephrine Interact to Predict Insulin Resistance: The VA Normative Aging Study. Psychosom Med, September 1, 2006; 68(5): 718 - 726. [Abstract] [Full Text] [PDF]

				M. Paul-Labrador, D. Polk, J. H. Dwyer, I. Velasquez, S. Nidich, M. Rainforth, R. Schneider, and C. N. B. Merz Effects of a randomized controlled trial of transcendental meditation on components of the metabolic syndrome in subjects with coronary heart disease. Arch Intern Med, June 12, 2006; 166(11): 1218 - 1224. [Abstract] [Full Text] [PDF]

				M. G. Marmot Status Syndrome: A Challenge to Medicine JAMA, March 15, 2006; 295(11): 1304 - 1307. [Full Text] [PDF]

				T. Chandola, E. Brunner, and M. Marmot Chronic stress at work and the metabolic syndrome: prospective study BMJ, March 4, 2006; 332(7540): 521 - 525. [Abstract] [Full Text] [PDF]

				K. M Oltmanns, B. Dodt, B. Schultes, H. H Raspe, U. Schweiger, J. Born, H. L Fehm, and A. Peters Cortisol correlates with metabolic disturbances in a population study of type 2 diabetic patients Eur. J. Endocrinol., February 1, 2006; 154(2): 325 - 331. [Abstract] [Full Text] [PDF]

				M.-H. Kim, M.-K. Kim, B. Y. Choi, and Y.-J. Shin Educational disparities in the metabolic syndrome in a rapidly changing society--the case of South Korea Int. J. Epidemiol., December 1, 2005; 34(6): 1266 - 1273. [Abstract] [Full Text] [PDF]

				K. E. Innes, C. Bourguignon, and A. G. Taylor Risk Indices Associated with the Insulin Resistance Syndrome, Cardiovascular Disease, and Possible Protection with Yoga: A Systematic Review J Am Board Fam Med, November 1, 2005; 18(6): 491 - 519. [Abstract] [Full Text] [PDF]

				B. J. Lehman, S. E. Taylor, C. I. Kiefe, and T. E. Seeman Relation of Childhood Socioeconomic Status and Family Environment to Adult Metabolic Functioning in the CARDIA Study Psychosom Med, November 1, 2005; 67(6): 846 - 854. [Abstract] [Full Text] [PDF]

				D. Lucini, G. Di Fede, G. Parati, and M. Pagani Impact of Chronic Psychosocial Stress on Autonomic Cardiovascular Regulation in Otherwise Healthy Subjects Hypertension, November 1, 2005; 46(5): 1201 - 1206. [Abstract] [Full Text] [PDF]

				N. Greenberg, M. Henderson, S. Karim, and K. Holland-Elliott Does having an occupational mental health service make any difference? Occup. Med., October 1, 2005; 55(7): 549 - 551. [Abstract] [Full Text] [PDF]

				Y. Liao, S. Takashima, N. Maeda, N. Ouchi, K. Komamura, I. Shimomura, M. Hori, Y. Matsuzawa, T. Funahashi, and M. Kitakaze Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism Cardiovasc Res, September 1, 2005; 67(4): 705 - 713. [Abstract] [Full Text] [PDF]

				R. Tauman, L. M. O'Brien, A. Ivanenko, and D. Gozal Obesity Rather Than Severity of Sleep-Disordered Breathing as the Major Determinant of Insulin Resistance and Altered Lipidemia in Snoring Children Pediatrics, July 1, 2005; 116(1): e66 - e73. [Abstract] [Full Text] [PDF]

				S Vale Psychosocial stress and cardiovascular diseases Postgrad. Med. J., July 1, 2005; 81(957): 429 - 435. [Abstract] [Full Text] [PDF]

H. Hemingway, M. Shipley, E. Brunner, A. Britton, M. Malik, and M. Marmot Does Autonomic Function Link Social Position to Coronary Risk?: The Whitehall II Study Circulation, June 14, 2005; 111(23): 3071 - 3077. [Abstract]